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Abstract 
Background: Peptidylarginine deiminase (PAD) post-translationally converts arginine residues to citrulline residues. 
Recent studies have suggested that PADI2 (PAD isoform 2), a member of the PAD family, is involved in the tumorigenic 
process of some tumors, especially breast cancer. However, little is known about the mechanisms of PADI2 in tumori-
genesis. This study aimed to elucidate the tumorigenic role and regulatory pathway of PADI2 in breast tumors.
Methods: The Sequenom MassARRAY and TaqMan genotyping methods were used to investigate the correlation 
between PADI2 gene SNPs and various tumor risks. PCR array analyses, including cancer pathway finder and signal 
transduction PCR arrays, were performed to investigate the tumorigenic pathway of PADI2 in the MCF-7 breast cancer 
cell line following treatment with anti-PADI2 siRNA. Cell proliferation, apoptosis and transwell migration assays were 
performed to observe the effect of PADI2 in MCF-7 cells treated with anti-PADI2 siRNA.
Results: Both Sequenom MassARRAY and TaqMan genotyping assays demonstrated that SNP rs10788656 in the 
PADI2 gene was significantly associated with breast cancer. PCR arrays indicated that inhibiting PADI2 expression 
significantly increased expression of CA9 and decreased expression of ACSL4 and BIRC3 in MCF-7 cells, which was 
verified using real-time PCR. Inhibiting PADI2 expression also significantly decreased the migration ability of MCF-7 
cells but did not affect cell proliferation or apoptosis.
Conclusions: The PADI2 gene confers susceptibility to breast cancer. PADI2 expression contributes to abnormal 
migration of breast tumor cells. PADI2 affects tumorigenesis in breast tumor cells by regulating the expression of 
ACSL4, BINC3 and CA9, which are known to promote abnormal lipid metabolism and cell invasion of tumors.
Keywords: Peptidylarginine deiminase (PAD), Citrullination, PADI2 (peptidylarginine deiminase isoform 2), ACSL4 
(long-chain fatty acyl-CoA synthetase 4), BIRC3 (baculoviral IAP repeat containing 3), CA9 (carbonic anhydrase IX)
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Background
Peptidylarginine deiminase (PAD) catalyzes the con-
version of arginine residues to citrulline residues in the 
presence of excessive calcium. This enzymatic reaction 
is referred to as citrullination or, alternatively, deimina-
tion. PAD-mediated post-translational citrullination 
plays important roles in protein function and structural 
stability and, therefore, significantly affects biochemical 
pathways by altering the structure and function of the 
substrates [1, 2]. Five mammalian PAD family members 
(PAD or PADI 1–4 and 6) are all encoded by a cluster of 
genes on chromosome 1p36.1 [3]. The pathological roles 
of the PAD family members and citrullination in patho-
genesis are garnering increasing interest [4, 5].
Peptidylarginine deiminase isoform 2 (PAD2/PADI2) 
has been implicated in cancer. McElwee et  al. found 
that PADI2 expression is regulated by EGF (epidermal 
growth factor) in mammary cancer cells and appears to 
play a role in the proliferation of normal mammary epi-
thelium. They furthermore found that PADI2 mRNA 
expression is highly correlated with HER2 (human 
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epidermal growth factor receptor-2), a well-known diag-
nostic maker for breast cancer, in a luminal breast cancer 
cell line [6]. Cherrington et  al. also found that EGF up-
regulates PADI2 transcription and translation in CMT25 
canine mammary tumor cells [7]. In addition, Bhattacha-
rya et  al. detected PADI2 expression and citrullination 
in glaucoma [8], and McElwee et  al. recently reported 
that PADI2 overexpression in transgenic mice promotes 
spontaneous skin neoplasia [9]. The above studies sup-
port a suggestion that PADI2 is involved in the tumo-
rigenic process of some tumors, especially breast cancer 
[10]. However, little is known about the detailed mecha-
nisms of PADI2 function during the tumorigenic process.
The present study investigated the possible associa-
tion between candidate SNPs (single nucleotide poly-
morphisms) in the PADI2 locus and various tumors. We 
aimed to determine whether these common polymor-
phisms in the PADI2 region are associated with various 
tumor risks using the Sequenom MassARRAY genotyp-
ing method. The genotyping result was verified using a 
TaqMan genotyping assay in independent cohorts. Based 
on the genotyping result, we focused on analyzing the 
tumorigenic role of PADI2 in cultured tumor cells. We 
also used a PCR array to investigate the regulatory path-
way of PADI2 in tumorigenesis. The PCR array result was 
verified with real-time PCR.
Results
Genotyping SNPs located in the PADI2 locus
Four tag SNPs were genotyped using samples from 
cohorts of patients with breast cancer, cervical carci-
noma, esophageal carcinoma, gastric carcinoma, liver 
cancer, lung cancer, ovarian cancer and rectal carcinoma 
and from healthy controls using the Sequenom Mas-
sARRAY system. The case–control analysis showed a 
significant difference in allele frequency and genotype 
frequency for rs2746533 in PADI2 between gastric car-
cinoma patients and controls. The analysis also showed 
a significant difference in allele frequency and genotype 
frequency for rs2076616 between gastric carcinoma 
patients and controls. In addition, the analysis showed a 
significant difference for rs10788656 between the follow-
ing groups: breast cancer patients and controls in geno-
type frequency; cervical carcinoma patients and controls 
in allele frequency; esophageal carcinoma patients and 
controls in allele frequency and genotype frequency; 
lung cancer patients and controls in allele frequency; 
and rectal carcinoma patients and controls in geno-
type frequency. The above results are shown in Table 1. 
Rs79395834 did not show single nucleotide polymor-
phisms in the Chinese population.
To verify the above results, genotyping for tag SNP 
rs10788656 was performed in samples from cohorts 
of patients with breast cancer, colon cancer, esopha-
geal cancer, cervical cancer, gastric cancer, liver cancer, 
lung cancer and rectal cancer and from healthy controls 
using the TaqMan method. Allele frequencies and gene 
frequencies of the SNP did not deviate from Hardy–
Weinberg Equilibrium (HWE) in both cases and con-
trols. The allele frequency (odds ratio 1.607331; 95 % CI 
[1.072208–2.409527], p = 0.020737) and gene frequency 
(p = 0.022085) for this SNP demonstrated a statistically 
significant association with breast cancer. Following mul-
tiple-test correction, this SNP still showed a significant 
difference in allele frequency and genotype frequency in 
breast cancer. Genotyping did not detect a significant dif-
ference in allele or genotype frequencies for rs10788656 
between patients with colon cancer, cervical cancer, 
esophageal cancer, gastric cancer, liver cancer, lung can-
cer or rectal cancer (p > 0.05).
Detecting cell proliferation, apoptosis and migration 
of MCF‑7 cells treated with anti‑PADI2 siRNA
The proliferation of MCF-7 cells that were treated with 
anti-PADI2 siRNA was measured using the CCK-8 assay. 
Real-time assay detected significantly decreased transcrip-
tion of PADI2 in the anti-PADI2 siRNA treated cells. A 
significant decline in cell proliferation was not detected in 
the siRNA-treated MCF-7 cells compared with cells that 
were treated with the Allstar siRNA (p =  0.152) and cells 
that were treated with only HiPerFect transfection reagent 
(p = 0.462). These results, which are shown in Fig. 1, suggest 
that PAD2 is not involved in regulating cell proliferation.
The effect of PADI2 on apoptosis in MCF-7 cells was 
determined using flow cytometric analysis with annexin 
V/PE and 7-AAD double staining. Compared with the 
Allstar siRNA treated cells (p  =  0.12) and cells treated 
with HiPerFect transfection reagent (p = 0.18), the num-
ber of apoptotic cells was not significantly changed in 
the anti-PADI2 siRNA-treated cells. The result, shown 
in Fig.  2, demonstrates that down-regulation of PADI2 
expression cannot induce apoptosis in MCF-7 cells.
MCF-7 cell migration was examined using a 2-com-
partment transwell system. A significantly decreased 
migration of MCF-7 cells was observed when PADI2 
expression was suppressed by anti-PADI2 siRNA 
compared with the cells treated with Allstar siRNA 
(p < 0.001) or HiPerFect transfection reagent (p < 0.001). 
The result, shown in Fig.  3, demonstrates that down-
regulation of PADI2 expression can inhibit migration of 
MCF-7 cells.
Determining the regulatory pathway of PADI2 in MCF‑7 
cells
The breast tumor cell line MCF-7 was treated with anti-
PADI2 siRNA. The cells treated with Allstar siRNA 
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were used as a negative control. The inhibition of PADI2 
expression was confirmed in the cultured tumor cells 
using real-time PCR. A series of Qiagen PCR arrays 
were used to examine the changes in gene expression 
in the tumor cell line and to determine the tumorigenic 
pathway. The cancer pathway finder PCR array revealed 
9 genes, including ACSL4, BIRC3,CA9, CCL2, FLT1, 
FOXC2, G6PD, IGFBP3 and SNAI2, with significantly 
altered expression in the siRNA-treated MCF-7 cells. 
The signal transduction PCR array detected 16 genes, 
including CA9, HEY2, ACSL4, ACSL5, BCL2A1, BIRC3, 
CEBPD, CSF1, FABP1, FOSL1, HES5, ICAM1, TNF, 
WNT3A and WNT6, with significantly altered expres-
sion in the treated cells. The results are shown in Fig. 4.
Real-time PCR was applied to verify the above PCR 
array analysis results. The increased expression of 
CA9 and decreased expression of BIRC3 and ACSL4 in 
MCF-7 cells was detected following treatment with the 
anti-PADI2 siRNA, which was consistent with the results 
of the PCR array analysis. These results are shown in 
Fig. 5. Other genes that were detected with significantly 
altered expression by PCR array, such as CCL2, were not 
confirmed by real-time PCR.
Discussion
In the present study, we used the Sequenom Mas-
sARRAY system to genotype the tag SNPs rs2746533, 
rs79395834, rs2076616 and rs10788656 in the PADI2 
locus to determine their association with susceptibil-
ity to various tumors. Analysis indicated that the SNPs 
rs2746533, rs2076616 and rs10788656 had a significant 
difference in allele frequency, genotype frequency or 
both between breast cancer, cervical carcinoma, gastric 
carcinoma, lung cancer and rectal carcinoma cases and 
the controls. The above genotyping result was verified 
using TaqMan assays in independent cohorts of various 
tumors. The analysis showed a significant difference in 
allele frequency and genotype frequency for rs10788656 
between breast cancer samples and the controls, which 
was completely consistent with the Sequenom Mas-
sARRAY result. The two genotyping methods with two 
independent cohorts provided the first evidence that the 
PADI2 gene confers susceptibility to breast cancer. We 
therefore focused on investigating the pathogenic mecha-
nism of PADI2 in breast cancer.
SNP rs10788656/rs58133422 is located in intron 1 
of the PADI2-encoding gene and is 6773  bp upstream 
from exon 2. Thus far, there have been no reports about 
the bio-function of this SNP. A tag SNP is a representa-
tive single nucleotide polymorphism in a region of the 
genome with high linkage disequilibrium that represents 
a group of SNPs called a haplotype. It is feasible to geno-
type a few tag SNPs to determine a potential association 
with phenotypes without genotyping every SNP in the 
chromosomal region. We will screen more SNPs in this 
region, especially in the exon region and its surrounding 
region, to find functional SNPs and determine how these 
SNPs affect PADI2 expression and the enzyme activity 
in which PADI2 has been implicated in some diseases 
and, more recently, in cancers. Cherrington et  al. dem-
onstrated that PADI2 is expressed in canine mammary 
gland epithelium and that levels of histone citrullination 
in this tissue correlate with PADI2 expression [10]. In 
another study, the authors found that normal human and 
canine mammary epithelia also showed strong cytoplas-
mic and nuclear expression of PADI2. However, PADI2 
expression was reduced in mammary carcinomas from 
both species. Feline mammary carcinomas had complete 
loss of nuclear PADI2 expression. The authors suggested 
that loss of nuclear PADI2 expression may therefore rep-
resent a marker of progression towards more aggressive 
neoplasia [11]. Additionally, McElwee et  al. reported 
that PADI2 expression increases during the transi-
































































Fig. 1 Proliferation of MCF-7 cells that were treated with anti-PADI2 
siRNA. a Real-time assay detected the PADI2 mRNA level in the anti-
PADI2 siRNA-treated cells. b CCK-8 assay detected viable cell numbers 
as represented by an O.D. value at 405 nm. The cells treated with 
HiPerFect transfection reagent were used as normal controls, and the 
cells treated with Allstar siRNA were used as negative controls
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breast carcinomas, with a strong peak for PADI2 expres-
sion and activity [6]. The authors recently reported that 
approximately 37  % of transgenic mice overexpressing 
PADI2 developed spontaneous neoplastic skin lesions. 
They then found that the human squamous cell carci-
noma cell line A431 with overexpressed PADI2 was more 
tumorigenic and contained elevated levels of markers 
for inflammation and epithelial-mesenchymal transi-
tion [9]. Cherrington et al. found that PADI2 expression 
is low in anestrus and has extensive expression in the 
entire epithelium of the mammary duct in late diestrus. 
EGF up-regulates PADI2 transcription and translation 
in CMT25 cells, a canine mammary tumor cell line. At 
the subcellular level, PADI2 is expressed in the cyto-
plasm, and to a lesser extent, the nucleus of these epithe-
lial cells [7]. In the present study, a significant decline in 
cell migration was detected in MCF-7 cells when PADI2 
transcription was suppressed by siRNA, indicating that 
PADI2 expression contributes to abnormal migration 
of breast tumor cells. This result is also in accordance 
with our finding about the role of the PADI2 gene in the 
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Fig. 2 Apoptosis in MCF-7 cells that were treated with anti-PADI2 siRNA, as measured using an annexin V cell apoptosis assay. a The cells were 
treated with anti-PADI2 siRNA. b The cells treated with Allstar siRNA were used as negative controls. c The cells without siRNA treatment were used 
as normal controls. d The result of the apoptosis assay is shown in a graph
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others indicate that PADI2 may function as an oncogene 
to mediate the tumorigenic process.
The tumorigenic pathway of PADI2 was analyzed in the 
MCF-7 tumor cell line using tumorigenesis-related PCR 
arrays. RNA interference with PADI2 expression resulted 
in significant alteration of the expression of some genes 
involved in tumor progress and signal transduction. Real-
time PCR verified the increased expression of CA9 and 
decreased expression of BIRC3 and ACSL4 in the breast 
cancer cell line.
Previous studies have shown that key enzymes involved 
in lipid metabolic pathways are differentially expressed 
in normal tissues compared with tumor tissues. ACSL4, 
which mainly esterifies arachidonic acid into arachidonoyl-
CoA, is increased in breast, colon and hepatocellular carci-
noma. Maloberti et al. reported that ACSL4 is significantly 
up-regulated in the highly aggressive MDA-MB-231 breast 
cancer cells and regulates the expression of cyclooxyge-
nase-2 (COX-2) [12]. Orlando et al. reached a similar con-
clusion [13]. Wu et  al. suggested that ACSL4 can serve 
as both a biomarker for and a mediator of an aggressive 
breast cancer phenotype [14]. The present study detected 
decreased expression of ACSL4 and decreased cell migra-
tion ability in MCF-7 cells treated with anti-PADI2 siRNA. 
Combined with the above findings, the present study sug-
gests that increased expression of PADI2 in breast cancer 
cells may contribute to aggressive activity by stimulating 
ACSL4 expression and the ACSL4-mediated lipid metabo-
lism signaling pathway.
The BIRC3 gene encodes a member of the IAP (inhibi-
tor of apoptosis proteins) family of proteins that inhibit 
apoptosis by binding to tumor necrosis factor receptor-
associated factors TRAF1 and TRAF2. BIRC3 was down-






































Fig. 3 Migration of MCF-7 cells that were treated with anti-PADI2 siRNA, as measured using a transwell migration assay. a The cells were treated 
with anti-PADI2 siRNA. b The cells treated with Allstar siRNA were used as negative controls. c The cells without siRNA treatment were used as nor-
mal controls. d The result of the migration measurement is shown in a graph. Original magnification: ×4.2
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epithelial cells [15, 16]. ER and NF-κB can up-regu-
late the anti-apoptotic activity of BIRC3. NF-κB, act-
ing through two response elements, is required for ER 
recruitment to an adjacent estrogen response element 
(ERE) in the BIRC3 promoter [17]. The current study 
detected decreased expression of BIRC3 in breast cancer 
cells when PADI2 expression was suppressed using anti-
PADI2 siRNA. It is possible that the increased expres-
sion of PADI2 in breast cancer cells up-regulates BIRC3 
expression through ER and NF-κB to simulate anti-apop-
totic functions.
CA9 catalyzes the reversible metabolism of carbon diox-
ide to carbonic acid and has been linked to malignant 
transformation and hypoxia in various cancers. CA9 is a 
powerful marker used to diagnose various types of meta-
static cancers, including cervical, renal, breast and head 
and neck tumors. Preclinical studies in cultured cells have 
clearly demonstrated that CA9 stimulates the metastatic 
properties of cancer cells. Expression of the CA9 protein 
and the BRCA1 (breast cancer 1) protein are inversely cor-
related in patients with breast cancer. Patients with high 
levels of CA9 expression show significantly worse overall 
survival. High CA9 protein expression occurs in patients 
with the BRCA1 mutant signature and low levels of the 
BRCA1 protein [18]. Hypoxia-regulated CA9 expression 
is associated with poor survival in patients with inva-
sive breast cancer [19, 20]. The current study detected 
increased expression of CA9 in the anti-PADI2 siRNA-
treated breast cancer cell lines, supporting the importance 
of the PADI2-CA9 pathway in breast cancer progression. 
In addition, some studies have reported that a subgroup 
of gastric cancers retains CA9 expression in cancer cells 
at the invasion front and that expression of CA9 is associ-
ated with increased invasion [21]. These findings and ours 
support the hypothesis that CA9 expression mediated by 
PADI2 may contribute to invasion and advanced tumor 
progression in breast cancer.
We previously detected increased expression of PADI4 
in a variety of malignant tissues and in the blood of 
tumor patients [22, 23]. We recently detected citrulli-
nation of α-enolase, heat shock protein 60, cytokeratin 
8 and tubulin beta in ECA, H292, HeLa, HEPG2, Lovo, 
MCF-7, PANC-1, SGC and SKOV3 tumor cell lines using 
proteomic methods [24]. Zhang et al. found that stimula-
tion of ER α-positive cells with 17 β-estradiol (E2) pro-
motes citrullination of histone H3 arginine 26 (H3R26) 
on chromatin. They further found that citrullination of 
H3R26 is catalyzed by PADI2, whereas H4R3 is catalyzed 
by PADI4. They suggested that estrogen stimulation 
induces the recruitment of PADI2 to target promoters by 
ERα, whereby PADI2 then catalyzes H3R26, which leads 
to local chromatin decondensation and transcriptional 
activation [25]. It is possible that both PADI2 and PADI4 
are expressed in breast tumor tissues and function by dif-
ferent pathogenic pathways.
This study potentially had intrinsic methodology limita-
tions. Some genes that may play important roles in tumo-
rigenesis are not included in the PCR arrays. In addition, 
genes with at least a fourfold change in expression were 
considered biologically significant in the study, based on 
the instructions of the manufacturer. Thus, some impor-
tant genes that are related to breast tumorigenesis may 
Result of  Cancer Pathwayfinder Pathway 






























Fig. 4 Determination of the regulatory pathway of PADI2 using PCR 
arrays. The tumor cell line MCF-7 was treated with anti-PADI2 siRNA. 
Cells treated with Allstar siRNA were used as a negative control. a 
PADI2 expression level was detected using real time-PCR in MCF-7 
cells following treatment with anti-PADI2 siRNA. The PADI2 transcrip-
tion level in the treated cells was normalized with the mRNA level in 
negative control cells. b Cancer pathway finder (c) Signal Transduc-
tion PCR arrays were used to detect altered expression of tumor-
related genes in the treated cells. Fold changes were calculated and 
expressed as log-normalized ratios of the expression level in siRNA-
treated cells/the expression level in negative control. Genes with at 
least a fourfold change in expression were considered biologically 
significant
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not have been analyzed in our study. In addition, we used 
cultured cell lines to investigate tumorigenic mecha-
nisms. The observed mechanisms may not be completely 
similar to the mechanisms in tumor tissues.
Conclusions
The present study demonstrated that PADI2 signifi-
cantly increases susceptibility to breast cancer. PADI2 
expression contributes to migration of breast tumor 
cells. Moreover, the study found that PADI2 can regulate 
ACSL4, BINC3 and CA9 expression to advance abnor-
mal lipid metabolism and cell invasion in breast tumors. 




Blood samples were collected in the Clinical Laboratory 
of Qilushihua General Hospital (Zibo, Shandong, China), 
a branch hospital of Shandong Provincial Qianfoshan 
Hospital. The tumor diagnosis was verified by histological 
methods, and pathological categorization was performed 
according to the World Health Organization (WHO) clas-
sification system. All patients signed informed consent 
forms, and the study was approved by the ethics commit-
tee of Shandong Provincial Qianfoshan Hospital.
Genomic DNA isolation and Sequenom MassARRAY 
genotyping
Peripheral blood samples were collected from patients 
with breast cancer (n  =  629, aged 25–73  years, 
mean 47.6  years), cervical carcinoma (n  =  258, aged 
25–78  years, mean 50  years), esophageal carcinoma 
(n = 397, 159 female, aged 41–81 years, mean 60 years), 
gastric carcinoma (n = 487, 217 female, aged 21–84 years, 
mean 56.9 years), liver cancer (n = 191, 35 female, aged 
25–86 years, mean 54.2 years), lung cancer (n = 506, 151 
female, aged 25–88 years, mean 59 years), ovarian cancer 
(n = 107, aged 19–78 years, mean 51.7 years) and rectal 
carcinoma (n = 162, 68 female, aged 21–79 years, mean 
55.2 years). A total of 760 (442 female, aged 17–87 years) 
healthy individuals with a mean age of 44.8 years donated 
Fig. 5 Determination of the mRNA expression levels of PADI2, ACSL4, BICR3 and CA9 in MCF-7 cells using real-time PCR. MCF-7 cells were treated 
with anti-PADI2 siRNA. Cells treated with Allstar siRNA were used as negative controls. The transcription levels of the target genes in the treated cells 
were normalized with their mRNA levels in negative control cells. a PADI2 expression in MCF-7 cells, b ACSL4 expression in MCF-7 cells, c BICR3 in 
MCF-7 cells, d CA9 in MCF-7 cells. ***p < 0.001
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blood. Blood samples were put into Monovette tubes 
containing 3.8  % sodium citrate. Genomic DNA was 
extracted from whole blood samples with the Omega E-Z 
96 Blood DNA kit (Omega, USA) according to the manu-
facturer’s protocol.
Tag single nucleotide polymorphisms (tag SNPs) 
across the PADI2 locus were identified by searching the 
HapMap database. Only SNPs with a minor allele fre-
quency (MAF) greater than 5 % and a pair-wise r2 ≥ 0.8 
were considered. Four tag SNPs, including rs2746533, 
rs79395834, rs2076616 and rs10788656, in the PADI2-
encoding gene were selected and genotyped using an 
allele-specific MALDI-TOF mass spectrometry assay 
(Sequenom MassARRAY). The polymorphism spanning 
fragments were amplified by PCR. Primers for the ampli-
fication and extension reactions were designed using 
MassARRAY Assay Design Version 3.1 software (Seque-
nom, San Diego, CA). Genotyping was then performed 
using the Sequenom MassARRAY iPLEX platform.
TaqMan genotyping
To verify the above genotyping result, tag SNP 
rs10788656 was selected for genotyping in new cohorts 
of patients with breast cancer (n  =  285, 285 women, 
mean age =  47.65), colon cancer (n =  144, 55 women, 
mean age  =  54.13), esophageal cancer (n  =  285, 40 
women, mean age  =  61.20), cervical cancer (n  =  190, 
190 women, mean age =  52.75), liver cancer (n =  190, 
42 women, mean age = 54.05), lung cancer (n = 190, 56 
women, mean age = 58.17), gastric cancer (n = 190, 44 
women, mean age = 56.97), and rectal cancer (n = 136, 
50 women, mean age = 54.61), as well as in healthy con-
trols (n = 285, 71 women, mean age = 40.1).
Genomic DNA was extracted as described above. The 
genomic DNA was diluted to a final concentration of 
15–20 ng/μl for the genotyping assays. The assays were run 
on a ViiA 7 DX (Life Technology) and evaluated according 
to the manufacturer’s instructions. Reactions were carried 
out in a total volume of 10 μl using the following amplifica-
tion protocol: denaturation at 95 °C for 10 min, 50 cycles 
of denaturation at 95  °C for 15 s and then annealing and 
extension at 60 °C for 1 min. The genotype of each sample 
was determined by measuring allele-specific fluorescence 
using the TaqMan Genotyper software V1.2 (Life Tech-
nology). Duplicate samples and negative controls were 
included to check the accuracy of genotyping.
Genotyping quality was examined by a detailed quality 
control procedure consisting of a >95 % successful call rate, 
duplicate calling of the genotypes, internal positive control 
samples and HWE testing. The SNPs were analyzed for 
association by comparing the MAF between the cases and 
controls. Dominant and recessive models were considered 
with respect to the minor allele. The association of the SNPs 
with diseases was evaluated using odds ratios (OR) with 
95 % confidence intervals (CI). Fisher’s exact test was used 
for comparisons between categorical variables. p values less 
than 0.05 were considered statistically significant. Geno-
typic association was assessed using Plink v1.07 (http://
pngu.mgh.harvard.edu/purcell/plink/) and SHEsis (http://
analysis.bio-x.cn/myAnalysis.php) software [26, 27]. Bon-
ferroni single-step correction was performed by Plink v1.07.
Cell culture and siRNA interference
The MCF-7 breast cancer cell line was cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented 
with 10 % fetal calf serum, 50 U/mL penicillin and 50 μg/
mL streptomycin in an atmosphere of 5 % CO2 at 37 °C. 
SiRNA oligonucleotides targeting the PADI2 gene (tar-
get sequence: 5′ CCCGTTCTTCGGCCAACGCTA 3′) 
were designed and synthesized by QIAGEN (Germany). 
The cultured tumor cells were transfected with siRNA at 
20  nM using the HiPerFect transfection reagent (QIA-
GEN) according to the manufacturer’s protocol. The cells 
were harvested for analysis 48 h after transfection. Paral-
lel experiments with Allstar siRNA were used as a nega-
tive control. Inhibition of PADI2 expression in the cell 
line was verified using real-time PCR.
PCR array analysis
Total RNA was isolated from the anti-PADI2 siRNA-
treated MCF-7 cells using Trizol solution (Invitrogen, 
USA) according to the manufacturer’s protocol. PCR 
arrays are sets of optimized real-time PCR primer assays 
in 96-well plates and are used to monitor the expres-
sion of genes related to a disease state or pathway. In this 
study, the Cancer PathwayFinder PCR array and Signal 
Transduction Pathway PCR array (Qiagen) were used 
to identify the pathogenic pathways of PADI2 in tumo-
rigenesis. The array layout is shown in Additional file 1. 
The PCR array analysis was conducted using a ViiA7 
DX instrument (Life Science) according to the manufac-
turer’s instructions. The procedure begins with the con-
version of experimental RNA samples into first-strand 
cDNA using the RT2 First Strand Kit. Next, the cDNA is 
mixed with an appropriate RT2 SYBR Green Mastermix. 
This mixture is aliquoted into the wells of the RT2 Profiler 
PCR Array. PCR is performed, and the relative expres-
sion level is determined using the data from the real-time 
cycler and the ∆∆CT method. The raw array data were 
processed and analyzed by the PCR array data analysis 
system at http://sabiosciences.com/pcrarraydataanalysis.
php. Fold changes were calculated and expressed as log-
normalized ratios of the siRNA treated cells/controls. 
Based on the instructions of the manufacturer, genes 
with at least a fourfold change in expression were consid-
ered biologically significant in the study.
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Real‑time PCR
Total RNA was extracted from tumor tissues or MCF-7 
cells and then reverse-transcribed in a final volume of 
10  μL using the RNA PCR Kit (TaKaRa, Japan). Real-
time PCR was conducted using a ViiA7 DX instrument 
according to the manufacturer’s protocol. The reactions 
were completed in a total volume of 10  µL, containing 
1 µL of cDNA, 5 µl of SYBR Green Real-time PCR Master 
Mix (ToYoBo, Japan) and 1 µL of each primer. PCR ampli-
fication cycles were performed using the following condi-
tions: 10 s at 95 °C, 40 cycles of 5 s at 95 °C and 31 s at 
60 °C. For each sample, two reactions were performed at 
the same time. One reaction was performed to determine 
the mRNA level of the target gene and the other to deter-
mine the β-actin level. PCR products were confirmed by 
melt curve analysis. Relative mRNA expression was calcu-
lated using the comparative threshold cycle (Ct) method. 
The relative target gene expression level was normalized 
to the β-actin mRNA expression level. Forward primer 
and reverse primer sequences for the amplification 
were as follows: PADI2: 5′ TGAAAGAGGTGAAGAA 
CCTTG 3′ and 5′ GTTTAGGTACTGGAAGCAGAC 
3′; β-actin: 5′-TGGCACCCAGCACAATGAA-3′ and 
5′-CTAAGTCATAGTCCGCCTAGAAGCA-3′; ACSL4 
(long-chain fatty acyl-CoA synthetase 4): 5′-CATAG 
CAATTTGATAGCTGGAA-3′ and 5′-TATCCAATCCTG 
CAGCCAT-3′; BIRC3 (baculoviral IAP repeat contain-
ing 3): 5′-GGTAACAGTGATGATGTCAAATG-3′ and 
5′-TAACTGGCTTGAACTTGACG-3′; CA9 (carbonic 
anhydrase IX): 5′-GCCTTTCTGGAGGAGGG-3′ and 
5′-AGATATGTCCAGTCCTGGG-3′.
Cell proliferation assay
MCF-7 cells were seeded into 96-well culture plates and 
incubated until they reached 80  % confluence. The cul-
ture was then treated with anti-PADI2 siRNA and incu-
bated for 24–72  h at 37  °C in 5  % CO2. Following the 
addition of 10 µl of Cell Counting Kit-8 (CCK-8, Dojindo) 
solution to each well, the cells were incubated for an 
additional 4  h. Absorbance was measured at 450  nm 
with a spectrophotometer (Spectramax 190; Molecular 
Devices). Growth curves were generated from the aver-
age values of five wells per group.
Cell apoptosis assay
Apoptosis in the siRNA-treated MCF-7 cells was ana-
lyzed using flow cytometry (FACSAria II, BD Bio-
sciences). The cultured cells were washed twice with 
PBS and were resuspended in binding buffer at a con-
centration of 1  ×  106  cells/mL. The cell suspensions 
(1 × 105 cells/100 µL) were transferred into 5-mL culture 
tubes, and 5 µL of annexin V-phycoerythrin (eBioscience) 
and 5 µL of 7-amino-actinomycin (eBioscience) were then 
added. The cells were gently vortexed and incubated at 
room temperature in the dark for 15 min. Subsequently, 
another 400-µL aliquot of binding buffer was added. Flow 
cytometry was performed within 4 h of staining.
Transwell migration assay
Transwell inserts (8.0-µm pore size) with a polycarbon-
ate filter (Costar ®) were used to examine the effects of 
PADI2 on cell migration. Anti-PADI2 siRNA-treated 
MCF-7 cells (5  ×  104 cells/200  µL) were suspended in 
serum-free media and added to the upper chamber, and 
500 µL of complete DMEM media was added to the lower 
chamber. Following incubation for 24  h, the filter was 
immersed in methanol for 15 min at room temperature 
and then was treated with 0.25 % crystal violet stain for 
10 min at room temperature prior to washing with water. 
The cells that had migrated to the lower side of the filter 
were counted with an inverted fluorescence microscope.
Statistical analysis
Data were analyzed using the two-tailed Student’s t 
test. Differences were considered significant at p < 0.05. 
Experiments were performed with triplicate samples and 
were performed three times or more to verify the results.
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